MiMedx is an industry leader in advanced wound care and a therapeutic biologics company. As a company, we are driven to bring hope to people with hard-to-heal wounds. Our ability to advance science will further differentiate the value of our business and set the foundation for our platform portfolio to address other areas of unmet need.
We pioneered the processing and use of dehydrated amniotic tissue, and currently develop and distribute human placental-based tissue allografts for multiple sectors of healthcare, including wound care, burn, and various surgical applications. In support of the company’s mission to improve patient lives and elevate the standard of care, MiMedx is also leading multiple clinical trials to explore applications in osteoarthritis, plantar fasciitis, and other degenerative musculoskeletal conditions. MiMedx has supplied over 2 million allografts, through both direct and consignment shipments.
Patients suffering from chronic, hard-to-heal wounds are one of the most underdiagnosed, undertreated, underserved populations. More than 30 million Americans have diabetes; close to three million of these people suffer from chronic wounds. Many will face serious complications—including repeated, unhealed wounds—that may lead to limb amputation. Our essential purpose is to provide advanced treatment options for these patients and the health professionals who serve them.